SBU – API
Cadila Pharmaceuticals Ltd. is one of the largest privately held pharmaceutical companies in India. Over the last six decades, our company has been developing and manufacturing pharmaceutical products in India and selling and distributing in over hundred countries around the world. Being an integrated pharmaceutical company, our presence is across the entire life sciences value chain i.e. R&D, API, formulations, marketing and development.
At Cadila, research plays a pivotal role, be it in bio-technology, APIs, formulations, plant tissue culture, vaccines, immuno-globulin, new drug discovery and phyto-chemistry. Our 350 scientists working across our dedicated R&D setups are testament to our competencies in undertaking research in therapeutic areas with high unmet medical needs.
Active Pharmaceutical Ingredients (API) Strategic Business Unit (SBU)
One of Cadila’s core business areas is to synthesize Active Pharmaceutical Ingredients (APIs) of the highest standard in an integrated cost effective manner. Spread over 80,000 square meter area, our manufacturing facility at Ankleshwar (India) is accredited by USFDA, European Directorate of Quality Medicine (EDQM), Agenzia Italiana del Farmaco (AIFA), Therapeutic Goods Administration (TGA – Australia), Pharmaceutical and Medical Device Agency (PMDA – Japan) and WHO (Geneva).
Some of the highlights are:
- Major presence in regulated markets – USA, Europe and Japan
- More than 30 APIs and intermediates
- Presence in more than 100 countries
- Diversified product portfolio covering leading therapeutic segments